A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase

Biochimica et Biophysica Acta - General Subjects

Volumn 1840, Issue 7, 2014, Pages 2203-2211

  Mislak, Andrea C ^a   Frey, Kathleen M ^a   Bollini, Mariela ^b   Jorgensen, William L ^b   Anderson, Karen S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Crystallography; HIV 1; NNRTI; Reverse transcriptase; Transient kinetics

Indexed keywords

DIARYLTRIAZINE DERIVATIVE; MORPHOLINE DERIVATIVE; MORPHOLINOPROPOXY DERIVATIVE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; POLYMERIZATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

CRYSTALLOGRAPHY; HIV-1; NNRTI; REVERSE TRANSCRIPTASE; TRANSIENT KINETICS;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; KINETICS; MECHANICAL PHENOMENA; MORPHOLINES; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; TRIAZINES;

EID: 84900002229     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2014.04.001     Document Type: Article

References (45)

1. E.J. Arts, and D.J. Hazuda HIV-1 antiretroviral drug therapy Cold Spring Harb. Perspect. Med. 2 2012 (a007161-a007161)
2. J.D. Roberts, K. Bebenek, and T.A. Kunkel The accuracy of reverse transcriptase from HIV-1 Science 242 1988 1171 1173
3. W.L. Jorgensen, and E.M. Duffy Prediction of drug solubility from structure Adv. Drug Deliv. Rev. 54 2002 355 366
4. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 2001 3 26
5. A.R. Ekkati, M. Bollini, R.A. Domaoal, K.A. Spasov, K.S. Anderson, and W.L. Jorgensen Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase Bioorg. Med. Chem. Lett. 22 2012 1565 1568
6. M. Bollini, J.A. Cisneros, K.A. Spasov, K.S. Anderson, and W.L. Jorgensen Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility Bioorg. Med. Chem. Lett. 23 2013 5213 5216
7. I. Weuts, F. Van Dycke, J. Voorspoels, S. De Cort, S. Stokbroekx, and R. Leemans et al. Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine J. Pharm. Sci. 100 2011 260 274
8. P.A.J.P. Janssen, P.J.P. Lewi, E.E. Arnold, F.F. Daeyaert, M.M. de Jonge, and J.J. Heeres et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6- dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine) J. Med. Chem. 48 2005 1901 1909
9. L.-Q. Sun, B. Qin, L. Huang, K. Qian, C.-H. Chen, and K.-H. Lee et al. Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors Bioorg. Med. Chem. Lett. 22 2012 2376 2379
10. X. Chen, P. Zhan, X. Liu, Z. Cheng, C. Meng, and S. Shao et al. Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors Bioorg. Med. Chem. 20 2012 3856 3864
11. S.G. Kerr, and K.S. Anderson Pre-steady-state kinetic characterization of wild type and 3"-azido-3-"deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance Biochemistry 36 1997 14064 14070
12. W.M. Kati, K.A. Johnson, L.F. Jerva, and K.S. Anderson Mechanism and fidelity of HIV reverse transcriptase J. Biol. Chem. 267 1992 25988 25997
13. A.S. Ray, E. Murakami, A. Basavapathruni, J.A. Vaccaro, D. Ulrich, and C.K. Chu et al. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis Biochemistry 42 2003 8831 8841
14. C.M. Bailey, T.J. Sullivan, P. Iyidogan, J. Tirado-Rives, R. Chung, and J. Ruiz-Caro et al. Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy J. Med. Chem. 56 2013 3959 3968
15. K.M. Frey, M. Bollini, A.C. Mislak, J.A. Cisneros, R. Gallardo-Macias, and W.L. Jorgensen et al. Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design J. Am. Chem. Soc. 134 2012 19501 19503
16. Z. Otwinowski, and W. Minor Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 276 1997 307 326
17. A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, and R.J. Read Phaser crystallographic software J. Appl. Crystallogr. 40 2007 658 674
18. A.J. McCoy Solving structures of protein complexes by molecular replacement with Phaser Acta Crystallogr. D Biol. Crystallogr. 63 2007 32 41
19. K. Das, J.D. Bauman, A.D. Clark, Y.V. Frenkel, P.J. Lewi, and A.J. Shatkin et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations Proc. Natl. Acad. Sci. U. S. A. 105 2008 1466 1471
20. K. Das, A.D. Clark, P.J. Lewi, J. Heeres, M.R. De Jonge, and L.M.H. Koymans et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants J. Med. Chem. 47 2004 2550 2560
21. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr. D Biol. Crystallogr. 60 2004 2126 2132
22. P.D. Adams, P.V. Afonine, G. Bunkóczi, V.B. Chen, I.W. Davis, and N. Echols et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. D Biol. Crystallogr. 66 2010 213 221
23. T.N. Bhat, and G.H. Cohen OMITMAP: an electron density map suitable for the examination of errors in a macromolecular model J. Appl. Crystallogr. 17 1984 244 248
24. The Pymol Molecular Graphics System, Version 1.5.0.4; Schrödinger, LLC.
25. R.A. Spence, W.M. Kati, K.S. Anderson, and K.A. Johnson Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors Science 267 1995 988 993
26. D.W. Ludovici, R.W. Kavash, M.J. Kukla, C.Y. Ho, H. Ye, and B.L. De Corte et al. Evolution of anti-HIV drug candidates. Part 2: diaryltriazine (DATA) analogues Bioorg. Med. Chem. Lett. 11 2001 2229 2234
27. E.B. Lansdon, K.M. Brendza, M. Hung, R. Wang, S. Mukund, and D. Jin et al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design J. Med. Chem. 53 2010 4295 4299
28. K. Das, P.J. Lewi, S.H. Hughes, and E. Arnold Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors Prog. Biophys. Mol. Biol. 88 2005 209 231
29. M. Bollini, K.M. Frey, J.A. Cisneros, K.A. Spasov, K. Das, and J.D. Bauman et al. Extension into the entrance channel of HIV-1 reverse transcriptase - crystallography and enhanced solubility Bioorg. Med. Chem. Lett. 23 2013 5209 5212
30. D.J. Kertesz, C. Brotherton-Pleiss, M. Yang, Z. Wang, X. Lin, and Z. Qiu et al. Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses Bioorg. Med. Chem. Lett. 20 2010 4215 4218
31. D.M. Himmel, K. Das, A.D. Clark, S.H. Hughes, A. Benjahad, and S. Oumouch et al. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains J. Med. Chem. 48 2005 7582 7591
32. M.L. Mitchell, J.C. Son, H. Guo, Y.-A. Im, E.J. Cho, and J. Wang et al. N1-alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase Bioorg. Med. Chem. Lett. 20 2010 1589 1592
33. J. Ren, P.P. Chamberlain, A. Stamp, S.A. Short, K.L. Weaver, and K.R. Romines et al. Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors J. Med. Chem. 51 2008 5000 5008
34. A.L. Hopkins, J. Ren, R.M. Esnouf, B.E. Willcox, E.Y. Jones, and C. Ross et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors J. Med. Chem. 39 1996 1589 1600
35. R. Esnouf, J. Ren, C. Ross, Y. Jones, D. Stammers, and D. Stuart Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors Nat. Struct. Biol. 2 1995 303 308
36. Y. Hsiou, J. Ding, K. Das, A.D. Clark, S.H. Hughes, and E. Arnold Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms Structure 4 1996 853 860
37. L.A. Kohlstaedt, J. Wang, J.M. Friedman, P.A. Rice, and T.A. Steitz Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor Science 256 1992 1783 1790
38. K. Das, S.E. Martinez, J.D. Bauman, and E. Arnold HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism Nat. Struct. Mol. Biol. 19 2012 253 259
39. E.B. Lansdon, D. Samuel, L. Lagpacan, K.M. Brendza, K.L. White, and M. Hung et al. Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex J. Mol. Biol. 397 2010 967 978
40. J. Ding, K. Das, Y. Hsiou, S.G. Sarafianos, A.D. Clark, and A. Jacobo-Molina et al. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution J. Mol. Biol. 284 1998 1095 1111
41. M.-P. De Béthune Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009) Antiviral Res. 85 2010 75 90
42. L. Tambuyzer, J. Vingerhoets, H. Azijn, B. Daems, S. Nijs, and M.-P. De Béthune et al. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies AIDS Res. Hum. Retroviruses 26 2010 1197 1205
43. V.A. Johnson, V. Calvez, H.F. Günthard, R. Paredes, D. Pillay, and R. Shafer et al. 2011 update of the drug resistance mutations in HIV-1 Top. Antivir Med. 19 2011 156 164
44. J. Ren, C.E. Nichols, A. Stamp, P.P. Chamberlain, R. Ferris, and K.L. Weaver et al. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138 FEBS J. 273 2006 3850 3860
45. K. Singh, B. Marchand, D.K. Rai, B. Sharma, E. Michailidis, and E.M. Ryan et al. Biochemical mechanism of HIV-1 resistance to rilpivirine J. Biol. Chem. 287 2012 38110 38123